An atlas of the human kinome reveals the mutational landscape underlying dysregulated phosphorylation cascades in cancer

Aleksandra Olow*, Zhongzhong Chen*, R. Hannes Niedner, Denise M. Wolf, Christina Yau, Aleksandr Pankov, Evelyn Pei Rong Lee, Lamorna Brown-Swigart, Laura J. van 't Veer, and Jean-Philippe Coppé

SUPPLEMENTARY FIGURES S1 to S17







Number of distinct heptameric peptide sequences 2000 500 0 7-mer 13-mer 9-mer 11-mer

d

2500

+1.0229%

+1.0181%

+1.0104%







Substrates

~	
-	

Disease category (Disease Onotology-terms were classified under 13 categories)	# of different DO terms per category	# of associated proteins per category	ontology details
Cancer	63	40	including malignant cancers, neoplasms, or hamartomas, across all tissue or cell types
Development anomalies	26	18	including congenital disorders, multisystem diseases, growth defects, mental retardation, intellectual disability
Cardio-vascular disorder conditions	23	14	including atherosclerosis, coronary artery disease, hypertension, cardiopathies
Neuropathies	18	14	including neurodegenerative disorders
Metabolic dysfunctions	11	9	including diabetes, obesity, insulin and glycemic dysregulation
Immune deficiencies	12	10	including auto-immune disorders
Infections	9	8	both viral & bacterial
Hematologic diseases	13	7	including anemic and bleeding disorders
Myelopathies	8	5	including bone marrow disorders
Myopathies	7	5	including muscular degenerative diseases
Mental or psychiatric affections	6	4	
Osteopathies	4	4	
Other	23	13	including disorders of eye, kidney, lung, skin, thyroid, digestive and reproductive system



AKT-centric



b





С



а

Node attribute: # of non-synonymous heptamer variants per substrate protein node

е



b









<u>A</u>		_		<u>C</u>
Protein name	# of peptides (per protein)	Avergae # of variants per peptide (per protein)	% of non- synonymous variants	Pro
	(x-axis)	(y-axis)	(color-code)	
FLT3	4	31.8	95.7	MA
NOS1	5	20.0	50.0	IRS
APC	3	14.0	57.0	EG
MYC	2	13.5	75.0	CH
ELK1	6	12.7	44.4	BR
DAPP1	4	12.5	100.0	CH
SPP1	4	12.0	100.0	RA
PPP1R14A	4	8.0	100.0	NE
XIAP	2	8.0	100.0	RB
ACP1	4	7.0	58.3	CB
CDK5 PLA2G4A	4	7.0	50.0 50.0	GJ
KRT8	5	6.6	60.0	MB
MAP4K1 GSK3B	5	6.6	20.0	PTI
CAV1	3	6.3	83.3	ES
GRIA1	6	6.0	83.3 82.5	CR
MAPK8	4	6.0	66.7	AD
DAB2	3	6.0	100.0	BC
SREBF1	2	6.0	66.7	CF
PTPRR	8	5.7	83.3	GY FO
MSN AMPH	3	5.7	50.0	BC
CDH1	5	5.2	85.0	GT MY
				RE
3				
	# of pentides	Avergae # of variants per	% of non-	NF
Protein name	(per protein)	peptide (per	synonymous	HN CD
		protein)	variants	PR
	(x-axis)	(y-axis)	(color-code)	CT CT
CTNNB1 TP53	17	34.4	59.6 80.7	PA
CDC25C	15	26.2	66.4	SY
CD79B PTEN	7	25.4	100.0	BIC
ETV1	11	10.4	90.9	CD
BDKRB2 KIT	16	10.1	52.1 81.4	INS
GFAP	15	8.8	65.7	BC
FCGR2A FFF2K	12	8.0	100.0	LIP
AKT1	16	7.6	46.9	ET
PLCG1 STAT3	15	6.8	3.3	DC
BAD	24	6.6	44.8	PD SY
GRM5 PLCG2	12	6.4	100.0	SM
HABP4	12	6.0	50.0	MA
SHC1	18	5.9	55.5	E2
SNCA	13	5.8	76.9	RP
RRAD	15	5.3	90.0	BM
CDX2	12	5.3	58.3	ITC
				LCI
		Avergae # of		GA JAI
Protein name	# of peptides	variants per	% of non- synonymous	PA
	(per protein)	peptide (per protein)	variants	CS
	(x-axis)	(y-axis)	(color-code)	CC
KBKB CREB1	24 11	0.0 0.0	0.0 0.0	DC FPI
STAT1 CDK1	11	0.0	0.0	MA PK
SSK3A	9	0.0	0.0	EP
PPP1R2	8	0.0	0.0	GR
ATF1 CHUK	6 6	0.0	0.0	YW
MTOR TCF7L2	6	0.0	0.0	MA
ADRA1B	5	0.0	0.0	FO
CDK6	5 5	0.0	0.0	ME
CFL1 DNM1	5	0.0	0.0	BT
EIF2S1	5	0.0	0.0	CD
RGS19	5	0.0	0.0	ME
ADD2 CLTB	4	0.0	0.0	AB
CRK EEE1B2	4	0.0	0.0	PT XP
HDAC1	4	0.0	0.0	HS
JUNB	4	0.0	0.0	CD
MAPK10 MAPK14	4	0.0	0.0	RA
MAPK15	4	0.0	0.0	IRA LM
NDE1	4	0.0	0.0	ER
NFKBIB RAD17	4	0.0	0.0	MA
RASA1	4	0.0	0.0	NE
STAT5A CDC6	4	0.0	0.0	CD

C			
Protein name	# of peptides (per protein)	Avergae # of variants per peptide (per protein)	% of non- synonymous variants
	(x-axis)	(y-axis)	(color-code)
KBKB	24	0.0	0.0
CREB1	11	0.0	0.0
STAT1	11	0.0	0.0
CDK1	9	0.0	0.0
GSK3A	9	0.0	0.0
HMGA1	8	0.0	0.0
PPP1R2	8	0.0	0.0
ATE1	6	0.0	0.0
CHUK	6	0.0	0.0
MTOR	6	0.0	0.0
TCF7L2	6	0.0	0.0
ADRA1B	5	0.0	0.0
ADRA2A	5	0.0	0.0
CDK6	5	0.0	0.0
CFL1	5	0.0	0.0
DNM1	5	0.0	0.0
FIE2S1	5	0.0	0.0
PEBP1	5	0.0	0.0
RGS19	5	0.0	0.0
ADD2	4	0.0	0.0
CLTB	4	0.0	0.0
CRK	4	0.0	0.0
EEF1B2	4	0.0	0.0
HDAC1	4	0.0	0.0
HDAC5	4	0.0	0.0
JUNB	4	0.0	0.0
MAPK10	4	0.0	0.0
MAPK14	4	0.0	0.0
MAPK15	4	0.0	0.0
MYCN	4	0.0	0.0
NDE1	4	0.0	0.0
NFKBIB	4	0.0	0.0
RAD17	4	0.0	0.0
RASA1	4	0.0	0.0
STAT5A	4	0.0	0.0
CDC6	3	0.0	0.0
CEBPB	3	0.0	0.0
EEF2	3	0.0	0.0
GRK1	3	0.0	0.0
INCENP	3	0.0	0.0
LIMK1	3	0.0	0.0
MAFA	3	0.0	0.0
NRGN	3	0.0	0.0
PPP1R9B	ă	0.0	0.0
RXRA	2	0.0	0.0
SH3BP2	3	0.0	0.0
SI C1242	3	0.0	0.0
SYNGAP1	3	0.0	0.0
TOB1	3	0.0	0.0

name	# of peptides (per protein)	Avergae # of variants per peptide (per protein)	% of non- synonymous variants
	(x-axis)	(y-axis)	(color-code)
	69 38	3.5 1.8	60.6 40.8
	38 23	1.4	43.9 55.0
BP1	22	1.7	9.1
i	21	1.7	58.7
	20	4.9	40.0
	19 18	3.4 3.9	42.1 68.1
A.	17	4.4 3.7	87.3 68.1
3	17	2.4	29.4 75.0
	15	3.5	66.7
	15	0.9	26.7
	15	4.1	95.2
	14 14	3.2	54.8 50.0
	14 14	1.9 1.6	14.3 53.6
1	14 13	1.2	46.4 26.9
	13	1.0	34.6
11	12	2.8	62.5
1	12	2.3	45.8
	12	2.0	66.0 40.3
	12 12	1.4 0.9	33.3 33.3
R1	11	3.1 2.5	65.2 67.6
∘к	11	2.4	86.4
iA	11	1.3	72.7
AP24	11	1.3	43.3
01	11	0.9	54.5 27.3
	11	0.8	45.5 9.1
	10	3.1	100.0
	10	2.4	70.0
	10	1.3	33.3
A4	10	0.8	25.0
	10 10	0.8	10.0 20.0
	9	3.2 2.9	55.6 84.8
	9	2.9	27.8
2	9	1.6	51.9
	9	1.0	29.6
	9	0.8	38.9
	9	0.4	33.3 75.0
1	8	4.5 3.6	68.8 25.0
1L	8	3.5 3.4	75.0 68.8
•	8	2.5	75.0
	8	2.4	75.0
8	8	1.6	81.3
2	8	1.0	75.0
u 1C	8	0.8	37.5 37.5
BIP1	8	0.6 0.6	20.8 15.6
	8	0.4	25.0 12.5
A I	7	4.6	45.2
z	7	2.7	14.3
	2	2.6	95.2
	7	2.4	56.0
	777	2.1	71.4 26.2
IA	777	1.9 1.9	81.0 78.6
}	7	1.7	85.7
	7	1.4	67.9
	2	1.3	42.9
в	777	1.1	57.1 28.6
D AP1	777	1.0 0.9	57.1 42.9
-	7	0.7	42.9
!	7	0.6	57.1
)	2	0.6	42.9
3 iB	7	0.4 0.3	28.6 28.6
	7	0.3	14.3





Proportion of SNPs among target regions from substrate proteins having the highest proportion of non-synonymous variants



Supplement Figure S10

d







Α

Kinases with the highest average # of HPR (V

	# of distinct		mean % non-
	neptameric	mean # of	synonymous
Kinase	regions	variants per	variants per
ame	phosphory-	HPR target	HPR target
	lated by the	per kinase	per kinase
	listed kinase		(% ISHPRV)
	(x-axis)	(y-axis)	(color-code)
DK6	1	39.0	84.6
л	5	19.0	82.5
LT3	7	18.7	95.4
DK9	3	15.3	87.0
SNK1D	15	6.6	81.1
KN2	19	6.3	84.1
aFR3	8	6.0	75.0
IIPKZ	5	6.0	91.7
RSK1	2	6.0	83.3
KSKZ	2	6.0	83.3
AKK3	1	6.0	83.3
CNDZ	1	5.0	100.0
DINKIE	19	4.5	87.0
	42	4.5	87.2
SNK1A1	75	4.5	79.4
	25	4.4	79.0
LNJ CCDDA	3	4.0	75.0
CGK3A	1	4.0	/5.0
AUKZ	1	4.0	50.0
UNT UNT	1	4.0	75.0
CK1	4	3.5	/8.0
	9	3.2	/5.0
CNICO	5/	3.2	81.0
DV1	29	3.2	100.0
KT3	6	3.0	100.0
N 1 3	2	3.0	100.0
HKA1	4	3.0	100.0
TINAL DUDA	4	3.0	66.7
	3	3.0	66.7
PH84 TV28		3.0	00.7
TK38	3	2.0	100.0
PH84 TK38 EK8	1	3.0	100.0

В Kinases with the highest # of targeted HPRs (x-axis extremes)

	# of distinct		mean % non-	
	heptameric	mean # of	synonymous	
Kinase	regions	variants per	variants per	
name	phosphory-	HPR target	HPR target	
	lated by the	per kinase	(% neHPRv)	
	listed kinase		(ve harn rev)	
	(x-axis)	(y-axis)	(color-code)	
CSNK2A1	213	2.8	81.3	
PRKCA	201	2.2	76.6	
PRKACA	195	2.1	83.1	
MAPK1	140	2.1	76.9	
SRC	128	1.9	80.3	
CDK1	124	1.7	74.8	
CSNK2A2	91	1.9	75.7	
AKT1	85	1.8	82.1	
CDK2	79	2.4	80.8	
SSK3B	75	4.5	79.4	
MAPK14	68	1.9	76.3	
ATM	67	2.6	84.8	
CDK5	57	3.2	81.0	
PRKCD	56	1.8	77.1	
МАРК8	53	2.9	63.4	
МАРКЗ	49	2.0	83.8	
PRKCB	48	1.8	83.1	
YN	47	2.3	76.1	
GFR	47	1.4	67.6	
CK	46	2.1	81.3	
CAMK2A	42	4.5	87.2	
YN	37	2.6	79.7	
NSR	35	2.5	79.6	
SYK	31	1.9	73.8	
КВКВ	31	1.2	87.5	
ROCK1	30	1.7	83.9	
PRKCG	30	1.7	79.5	
SNK2B	29	3.2	75.9	
PRKDC	28	2.9	88.0	
PDPK1	28	1.3	80.0	
ABL1	27	1.5	61.9	
ADRBK1	26	2.1	82.6	
AK2	26	1.9	63.0	
RKG1	26	1.8	85.7	
SNK1A1	25	4.4	79.0	
ATR	25	2.4	85.4	
	25	1.8	71.4	
RRR4	23	1.0	60.0	
RBB3	23	2.0	66.7	
PS6KA1	22	2.0	875	
NF BUILAL DI K1	22	2.0	87.5	
TK10	22	1.5	04.2	
DET	21	2.1	67.9	
1070	21	2.0	34.2	
LAP / U	21	1.3	/5.0	

0	
C	

Kinases with the lowest # of variants per targeted HPR

mean % of non-synonymous Heptameric Peptide Region variants (nsHPRv) per total

100%

50%

Kinase name	# of distinct heptameric peptide regions	mean # of variants per	mean % non- synonymous
Kinase name	peptide regions	mean # of variants per	synonymous
Kinase name	regions	variants per	variante por
name		LIDD Louis L	variants per
	phosphory-	HPR target	HPR target
	lated by the	per kinase	(% nsHPRv)
	listed kinase	(second a)	(sector and a)
MADOKAA	(x-axis)	(y-axis)	(color-code)
DBKACC		0.0	0.0
FEEDK	4	0.0	0.0
EEF2K	3	0.0	0.0
	3	0.0	0.0
IGF1R	2	0.0	0.0
MAPKIS	2	0.0	0.0
INLK DKAAVT1	2	0.0	0.0
	2	0.0	0.0
TESKI	2	0.0	0.0
TESK2	2	0.0	0.0
ACVR1	1	0.0	0.0
BRD4	1	0.0	0.0
CAD	1	0.0	0.0
CCNA2	1	0.0	0.0
CDK16	1	0.0	0.0
CDK19	1	0.0	0.0
CDK20	1	0.0	0.0
CLK4	1	0.0	0.0
CRK	1	0.0	0.0
DAPK2	1	0.0	0.0
DDR1	1	0.0	0.0
EIF2AK1	1	0.0	0.0
EIF2AK3	1	0.0	0.0
LIMK2	1	0.0	0.0
MAP3K10	1	0.0	0.0
MAP3K11	1	0.0	0.0
MAP3K3	1	0.0	0.0
MAP3K9	1	0.0	0.0
MAPK4	1	0.0	0.0
MAPK6	1	0.0	0.0
MELK	1	0.0	0.0
MYT1	1	0.0	0.0
NRK	1	0.0	0.0
PEG3	1	0.0	0.0
PINK1	1	0.0	0.0
PRKAR2A	1	0.0	0.0
PRKD3	1	0.0	0.0
PRKRIR	1	0.0	0.0
TRPM7	1	0.0	0.0
UHMK1	1	0.0	0.0
A REAL PROPERTY OF	-	0.0	0.0
WFF2	1	0.0	0.0

b Kinases with the highest average of non-

Synonymou	IS HER Val	iants per la	ilgeleu HFr
Kinase name	# of distinct heptameric peptide regions phosphory- lated by the	mean # of variants per HPR target per kinase	mean % non- synonymous variants per HPR target per kinase (% nsHPRv)
СНИК	11	17	100.0
TEC	7	2.0	100.0
GSK3A	7	1.8	100.0
GRK1	. 6	3.0	100.0
MAP3K7	6	2.8	100.0
PTK6	6	1.5	100.0
BUB1	6	1.0	100.0
PAK3	5	2.3	100.0
MAP3K5	5	1.8	100.0
BMPR1B	5	1.0	100.0
ERBB2	5	1.0	100.0
OXSR1	4	3.0	100.0
BLK	4	2.0	100.0
RPS6KA2	4	1.5	100.0
TAF1	4	1.5	100.0
FER	4	1.3	100.0
STK4	4	1.3	100.0
ABL2	4	1.0	100.0
MAPKAPK3	4	1.0	100.0
CAMKK1	3	2.0	100.0
RPS6KA4	3	2.0	100.0
SIK1	3	2.0	100.0
SIK3	3	2.0	100.0
FGR	3	1.5	100.0
AURKA	3	1.0	100.0
CLK2	3	1.0	100.0
EGER4	3	1.0	100.0
IRAK1	3	1.0	100.0
PRKAR1A	3	1.0	100.0
TYK2	3	1.0	100.0
EPHB1	2	2.0	100.0
PKM	2	2.0	100.0
RPS6KB1	2	2.0	100.0
SIK2	2	2.0	100.0
TGFBR1	2	2.0	100.0
WEE1	2	2.0	100.0
DAPK1	2	1.5	100.0
DYRK1B	2	1.5	100.0
BCR	2	1.0	100.0
CAMK2D	2	1.0	100.0
CDK8	2	1.0	100.0
EPHB2	2	1.0	100.0
FRK	2	1.0	100.0
IRAK4	2	1.0	100.0
MAP2K3	2	1.0	100.0
NME1-NME2	2	1.0	100.0
NME2	2	1.0	100.0
RAD17	2	1.0	100.0
CCND2	1	5.0	100.0
NEK8	1	3.0	100.0
ACVR1B	1	2.0	100.0
CSF1R	1	2.0	100.0
MAP4K1		2.0	100.0
MAIK	1	2.0	100.0
PKD1	-	2.0	100.0
PTPN11		2.0	100.0
STK3	1	2.0	100.0
BCAT2	1	1.0	100.0
CCNE1	1	1.0	100.0
CSNK1G1	1	1.0	100.0
DAPK3	1	1.0	100.0
DMPK	1	1.0	100.0
HIPK3	1	1.0	100.0
NEK2	1	1.0	100.0
PRKCI	1	1.0	100.0
PRKY	1	1.0	100.0
IAOK1	1	1.0	100.0
TTN	1	1.0	100.0
ZRANB2	1	1.0	100.0
		1.0	100.0



Protein that functions as a kinase only; the diameter increases proportionally with the number of substrates it phosphorylates.

Protein that functions both as a kinase and a substrate; the diameter increases proportionally to the sum of all of kinases phosphorylating it and all substrates it phosphorylates.

Protein that functions as a substrate only; the diameter increases proportionally with the number of kinases phosphorylating it

-- phosphorylation with unknown target site

individual phosphorylation on a known target site (with no known non-synonymous mutation within the immediate target site range); residue target sites are annotated in the middle of each connector
individual phosphorylation on a known target site with one or more known non-synonymous mutation(s) within the immediate target site range; the line width increases with the number of mutations

O margin increases proportionally with the number of known non-synonymous mutations within the immediate range of any target site



Protein that functions as a kinase only; the diameter increases proportionally with the number of substrates it phosphorylates.

Protein that functions both as a kinase and a substrate; the diameter increases proportionally to the sum of all of kinases phosphorylating it and all substrates it phosphorylates.

Protein that functions as a substrate only; the diameter increases proportionally with the number of kinases phosphorylating it

-- phosphorylation with unknown target site

individual phosphorylation on a known target site (with no known non-synonymous mutation within the immediate target site range); residue target sites are annotated in the middle of each connector
individual phosphorylation on a known target site with one or more known non-synonymous mutation(s) within the immediate target site range; the line width increases with the number of mutations

O margin increases proportionally with the number of known non-synonymous mutations within the immediate range of any target site















PLCG1 SYK SRC ERBB4 ERBB3 1559 Y783 Y771 LYN Y78 EGFR Y 7 83 1253 PLCGI ¥77 нск 771 ¥783 RET \$1248 NTRK1 NTRK2 FGFR1 PRKD

